The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Insulin Glargine Market Research Report 2024
Synopsis
nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
The global Insulin Glargine market was valued at US$ 6708 million in 2023 and is anticipated to reach US$ 8856.1 million by 2030, witnessing a CAGR of 4.0% during the forecast period 2024-2030.
Global Insulin Glargine key players include Sanofi-Aventis, Ganlee, etc. Global top two manufacturers hold a share nearly 50%.
USA is the largest market, with a share over 60%, followed by China, and Europe, both have a share about 35 percent.
In terms of product, Pre-filled Syringe is the largest segment, with a share about 75%. And in terms of application, the largest application is Treat type2 diabetes, followed by Treat type1 diabetes.
This report aims to provide a comprehensive presentation of the global market for Insulin Glargine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Insulin Glargine.
Report Scope
The Insulin Glargine market size, estimations, and forecasts are provided in terms of sales volume (M mL) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Insulin Glargine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Insulin Glargine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi-Aventis
Ganlee
Biocon
Segment by Type
Single Dose Vial
Pre-filled Syringe
Segment by Application
Treat Type2 Diabetes
Treat Type1 Diabetes
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Insulin Glargine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Insulin Glargine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
The global Insulin Glargine market was valued at US$ 6708 million in 2023 and is anticipated to reach US$ 8856.1 million by 2030, witnessing a CAGR of 4.0% during the forecast period 2024-2030.
Global Insulin Glargine key players include Sanofi-Aventis, Ganlee, etc. Global top two manufacturers hold a share nearly 50%.
USA is the largest market, with a share over 60%, followed by China, and Europe, both have a share about 35 percent.
In terms of product, Pre-filled Syringe is the largest segment, with a share about 75%. And in terms of application, the largest application is Treat type2 diabetes, followed by Treat type1 diabetes.
This report aims to provide a comprehensive presentation of the global market for Insulin Glargine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Insulin Glargine.
Report Scope
The Insulin Glargine market size, estimations, and forecasts are provided in terms of sales volume (M mL) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Insulin Glargine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Insulin Glargine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi-Aventis
Ganlee
Biocon
Segment by Type
Single Dose Vial
Pre-filled Syringe
Segment by Application
Treat Type2 Diabetes
Treat Type1 Diabetes
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Insulin Glargine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Insulin Glargine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Insulin Glargine Market Overview
1.1 Product Overview and Scope of Insulin Glargine
1.2 Insulin Glargine Segment by Type
1.2.1 Global Insulin Glargine Market Value Comparison by Type (2024-2030)
1.2.2 Single Dose Vial
1.2.3 Pre-filled Syringe
1.3 Insulin Glargine Segment by Application
1.3.1 Global Insulin Glargine Market Value by Application: (2024-2030)
1.3.2 Treat Type2 Diabetes
1.3.3 Treat Type1 Diabetes
1.4 Global Insulin Glargine Market Size Estimates and Forecasts
1.4.1 Global Insulin Glargine Revenue 2019-2030
1.4.2 Global Insulin Glargine Sales 2019-2030
1.4.3 Global Insulin Glargine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Insulin Glargine Market Competition by Manufacturers
2.1 Global Insulin Glargine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Insulin Glargine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Insulin Glargine Average Price by Manufacturers (2019-2024)
2.4 Global Insulin Glargine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Insulin Glargine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Insulin Glargine, Product Type & Application
2.7 Insulin Glargine Market Competitive Situation and Trends
2.7.1 Insulin Glargine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Insulin Glargine Players Market Share by Revenue
2.7.3 Global Insulin Glargine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Insulin Glargine Retrospective Market Scenario by Region
3.1 Global Insulin Glargine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Insulin Glargine Global Insulin Glargine Sales by Region: 2019-2030
3.2.1 Global Insulin Glargine Sales by Region: 2019-2024
3.2.2 Global Insulin Glargine Sales by Region: 2025-2030
3.3 Global Insulin Glargine Global Insulin Glargine Revenue by Region: 2019-2030
3.3.1 Global Insulin Glargine Revenue by Region: 2019-2024
3.3.2 Global Insulin Glargine Revenue by Region: 2025-2030
3.4 North America Insulin Glargine Market Facts & Figures by Country
3.4.1 North America Insulin Glargine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Insulin Glargine Sales by Country (2019-2030)
3.4.3 North America Insulin Glargine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Insulin Glargine Market Facts & Figures by Country
3.5.1 Europe Insulin Glargine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Insulin Glargine Sales by Country (2019-2030)
3.5.3 Europe Insulin Glargine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Insulin Glargine Market Facts & Figures by Country
3.6.1 Asia Pacific Insulin Glargine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Insulin Glargine Sales by Country (2019-2030)
3.6.3 Asia Pacific Insulin Glargine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Insulin Glargine Market Facts & Figures by Country
3.7.1 Latin America Insulin Glargine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Insulin Glargine Sales by Country (2019-2030)
3.7.3 Latin America Insulin Glargine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Insulin Glargine Market Facts & Figures by Country
3.8.1 Middle East and Africa Insulin Glargine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Insulin Glargine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Insulin Glargine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Insulin Glargine Sales by Type (2019-2030)
4.1.1 Global Insulin Glargine Sales by Type (2019-2024)
4.1.2 Global Insulin Glargine Sales by Type (2025-2030)
4.1.3 Global Insulin Glargine Sales Market Share by Type (2019-2030)
4.2 Global Insulin Glargine Revenue by Type (2019-2030)
4.2.1 Global Insulin Glargine Revenue by Type (2019-2024)
4.2.2 Global Insulin Glargine Revenue by Type (2025-2030)
4.2.3 Global Insulin Glargine Revenue Market Share by Type (2019-2030)
4.3 Global Insulin Glargine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Insulin Glargine Sales by Application (2019-2030)
5.1.1 Global Insulin Glargine Sales by Application (2019-2024)
5.1.2 Global Insulin Glargine Sales by Application (2025-2030)
5.1.3 Global Insulin Glargine Sales Market Share by Application (2019-2030)
5.2 Global Insulin Glargine Revenue by Application (2019-2030)
5.2.1 Global Insulin Glargine Revenue by Application (2019-2024)
5.2.2 Global Insulin Glargine Revenue by Application (2025-2030)
5.2.3 Global Insulin Glargine Revenue Market Share by Application (2019-2030)
5.3 Global Insulin Glargine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sanofi-Aventis
6.1.1 Sanofi-Aventis Corporation Information
6.1.2 Sanofi-Aventis Description and Business Overview
6.1.3 Sanofi-Aventis Insulin Glargine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sanofi-Aventis Insulin Glargine Product Portfolio
6.1.5 Sanofi-Aventis Recent Developments/Updates
6.2 Ganlee
6.2.1 Ganlee Corporation Information
6.2.2 Ganlee Description and Business Overview
6.2.3 Ganlee Insulin Glargine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Ganlee Insulin Glargine Product Portfolio
6.2.5 Ganlee Recent Developments/Updates
6.3 Biocon
6.3.1 Biocon Corporation Information
6.3.2 Biocon Description and Business Overview
6.3.3 Biocon Insulin Glargine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biocon Insulin Glargine Product Portfolio
6.3.5 Biocon Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Insulin Glargine Industry Chain Analysis
7.2 Insulin Glargine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Insulin Glargine Production Mode & Process
7.4 Insulin Glargine Sales and Marketing
7.4.1 Insulin Glargine Sales Channels
7.4.2 Insulin Glargine Distributors
7.5 Insulin Glargine Customers
8 Insulin Glargine Market Dynamics
8.1 Insulin Glargine Industry Trends
8.2 Insulin Glargine Market Drivers
8.3 Insulin Glargine Market Challenges
8.4 Insulin Glargine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
